Advances in Radiation Oncology


Publication Venue For

  • Why an Increasing Number of Unmatched Residency Positions in Radiation Oncology? A Survey of Fourth-Year Medical Students.  6. 2021
  • Leptomeningeal disease and neurologic death after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis.  6. 2021
  • Automated Contouring of Contrast and Noncontrast Computed Tomography Liver Images With Fully Convolutional Networks.  6. 2021
  • Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.  6. 2021
  • Students’ Perspectives and Concerns for the 2020 to 2021 Radiation Oncology Interview Season.  6. 2021
  • Interinstitutional Plan Quality Assessment of 2 Linac-Based, Single-Isocenter, Multiple Metastasis Radiosurgery Techniques.  5:1051-1060. 2020
  • Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage.  5:929-935. 2020
  • Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease.  5:34-42. 2020
  • Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma.  5:111-119. 2020
  • Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer.  4:649-658. 2019
  • Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.  4:90-95. 2019
  • The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgery.  3:421-430. 2018
  • Fractionated stereotactic radiation therapy for intact brain metastases.  2:564-571. 2017
  • Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.  2:259-269. 2017
  • A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.  1:83-88. 2016
  • Electronic International Standard Serial Number (eissn)

  • 2452-1094